相关实验视频

Updated: Jul 8, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

前列腺癌进展和治疗耐药性的新标志

Jason Wang¹, Reuben Ben-David^1,2, Reza Mehrazin^1,2

¹Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Expert opinion on therapeutic targets

|December 18, 2023

概括

了解前列腺癌 (PCa) 进展到抵抗割的PCa (CRPC) 是复杂的. 结合奥米克和表型标记的多模式签名对于监测晚期疾病和治疗耐药性至关重要.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

前列腺癌 (PCa) 呈现出显著的异质性,复杂化了晚期疾病的监测和进展到耐割PCa (CRPC).
通过转录组学进行瘤微环境分析,确定了与复发,转移和治疗耐药性相关的基因特征.
目前的治疗策略和生物标志物发现面临挑战,原因是先进的CRPC中远程转移和治疗耐药性.

研究的目的:

审查驱动PCa进展到致命疾病的分子决定因素.
讨论细胞可塑性的作用,表皮层-介质细胞过渡 (EMT) -介质细胞-表皮层过渡 (MET) 的相互转换,以及PCa转移中的信号通路.
评估液体活检的实用性,包括循环瘤细胞和细胞外囊泡,用于检测疾病进展和治疗耐药性.

主要方法:

关于相关研究的综合文献综述.
转录组数据和基因签名的分析.
讨论来自PubMed门户网站文献的发现.

主要成果:

PCa的异质性和复杂性阻碍了对晚期疾病和CRPC进展的准确监测.
来自瘤微环境分析的基因签名可以预测复发,入侵,转移和耐药性.
液体活检提供了检测疾病进展和耐药性出现的潜力.

结论:

没有一个单一的签名可以捕捉到PCa的全部异质性;需要多式联络签名.
综合omics衍生和表型标记的多式签名对于全面的监测至关重要.
解决治疗耐药性和转移需要更深入地了解PCa的分子驱动因素.

关键词:

细胞的可塑性细胞的可塑性细胞外囊泡中的细胞外囊泡.致命的疾病致命的疾病.转移转移转移转移复发性瘤的复发情况治疗失败的治疗失败.

更多相关视频

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...